Sigrid Therapeutics Secures $4 Million in Oversubscribed Funding Round to Tap Into Booming Obesity and Diabetes Market

Both Nordic and international investors were attracted by Sigrid's natural, non-drug alternative SiPore® technology

Sigrid Therapeutics successfully secured $4 million in an oversubscribed funding round. The investment, made by both existing and new investors, underlines the strong investor confidence in Sigrid’s innovative SiPore® technology.

The funds will be instrumental in accelerating the commercialisation of SiPore® across diverse markets, including medical devices, food supplements, veterinary, and oral health. SiPore21®, the company’s flagship product, is currently undergoing SHINE clinical trials as a natural, non-drug solution for prediabetes progression and weight control. Administered orally, SiPore21® utilises a carefully engineered, mesoporous silica mineral to prevent digestive enzymes from breaking down carbohydrates and fats, offering a promising alternative to pharmaceutical methods.

“This funding will propel our efforts in establishing key partnerships and driving SiPore® technology to market. We are thrilled to have the backing of our investors as we move closer to providing effective solutions for obesity and diabetes management,” says Sana Alajmovic, Co-Founder and CEO of Sigrid Therapeutics.

“Sigrid’s continued success is evident from the launch of one of the world’s largest prediabetes trial, SHINE, to SiPore21®’s medical device classification and the commercial traction in our oral health vertical. These accomplishments show the company is well on track to deliver on its exciting potential,” adds Mattias Ankarberg, Sigrid’s Chairman.

“We’re pleased that Sigrid Therapeutics’ recent share offering was oversubscribed by an impressive 50%. In today’s challenging financial climate, this achievement underscores the company’s quality and potential. Amidst concerns about obesity and diabetes, the demand for effective, non-drug therapies is evident. This success mirrors investor confidence and Sigrid’s commitment to pioneering drug-free solutions,” adds Lars Molinder, financial adviser to Sigrid Therapeutics.

Hot this week

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump